Raytheon Technologies Co. (NYSE: RTX) EVP Frank R. Jimenez sold 19,713 shares of the company in a transaction dated Wednesday, April 28. The stock was sold at an average price of $ 82.47, for a total trade of $ 1,625,731.11. Following the closing of the sale, the Executive Vice President now owns 62,221 shares of the company, valued at approximately $ 5,131,365.87. The transaction was disclosed in a document filed with the SEC, available at this hyperlink.
NYSE: RTX opened at $ 83.24 on Monday. Raytheon Technologies Co. has a one-year low of $ 51.13 and a one-year high of $ 83.80. The company has a leverage ratio of 0.45, a quick ratio of 0.95, and a current ratio of 1.22. The company has a market cap of $ 126.12 billion, a P / E ratio of -71.76, a P / E / G ratio of 1.67 and a beta of 1.39. The company has a 50-day simple moving average of $ 78.43 and a 200-day simple moving average of $ 71.29.
Raytheon Technologies (NYSE: RTX) last released its quarterly earnings data on Monday, April 26. The company reported EPS of $ 0.90 for the quarter, beating the consensus estimate of $ 0.88 by $ 0.02. The company posted revenue of $ 15.25 billion in the quarter, compared to $ 15.27 billion according to analysts’ estimates. Raytheon Technologies had a negative net margin of 3.77% and a positive return on equity of 8.35%. Raytheon Technologies revenue increased 34.3% year over year. In the same quarter of the previous year, the company posted EPS of $ 1.78. On average, research analysts predict that Raytheon Technologies Co. will post an EPS of 3.01 for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, June 17. Shareholders of record on Friday, May 21 will receive a dividend of $ 0.51 per share. This is a positive change from Raytheon Technologies’ previous quarterly dividend of $ 0.48. The ex-dividend date is Thursday, May 20. This represents a dividend of $ 2.04 on an annualized basis and a return of 2.45%. Raytheon Technologies’ dividend payout ratio is currently 23.00%.
Several research companies have recently published reports on RTX. Susquehanna raised its price target for Raytheon Technologies stock from $ 91.00 to $ 97.00 and rated the stock “positive” in a report on Wednesday, April 28. Wolfe Research began covering shares of Raytheon Technologies in a report on Thursday, April 15. They issued an “outperformance” rating and a price target of $ 97.00 for the company. Credit Suisse Group raised its price target for Raytheon Technologies shares from $ 81.00 to $ 90.00 and gave the stock an “outperformance” rating in a Tuesday April 20 report. Zacks investment research downgraded Raytheon Technologies shares from a “buy” rating to a “keep” rating and set a price target of $ 88.00 for the company. in a report on Friday. Finally, Morgan Stanley raised its price target on shares of Raytheon Technologies from $ 89.00 to $ 97.00 and gave the company an “overweight” rating in a research report on Wednesday April 28. Three analysts rated the stock with a sustaining rating, thirteen gave the stock a buy rating and one rated the stock as strong. The company currently has an average rating of “Buy” and an average target price of $ 84.47.
A number of institutional investors have recently changed their holdings in RTX. Schonfeld Strategic Advisors LLC increased its stake in Raytheon Technologies by 921.4% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 146,895 shares of the company valued at $ 8,452,000 after purchasing an additional 132,513 shares in the last quarter. Kathmere Capital Management LLC purchased a new stake in shares of Raytheon Technologies in the 3rd quarter valued at $ 60,000. Strategic Wealth Advisors Group LLC purchased a new stake in shares of Raytheon Technologies in the third quarter valued at $ 923,000. WealthPLAN Partners LLC purchased a new stake in shares of Raytheon Technologies in the 3rd quarter valued at $ 210,000. Finally, Thomasville Banque Nationale increased its holdings of Raytheon Technologies shares by 1.5% in the fourth quarter. Thomasville National Bank now owns 150,255 shares of the company valued at $ 10,745,000 after acquiring 2,251 additional shares during the last quarter. Institutional investors and hedge funds hold 75.09% of the company’s shares.
Raytheon Technologies Company Profile
Raytheon Technologies Corporation, an aerospace and defense company, provides systems and services to commercial, military and government customers around the world. It operates through four segments: Collins Aerospace Systems, Pratt & Whitney, Raytheon Intelligence & Space and Raytheon Missiles & Defense.
Featured article: What are the most popular green investment opportunities?
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured article: Systematic risk
7 health actions serving innovation in 2021
We all knew that traditional health care services were disrupted in 2020. The patient-doctor relationship has gone virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have this option available to them. And even local pharmacies have taken on a new role in e-commerce, as door-to-door pickup or door-to-door delivery of prescription drugs has become the norm.
So it’s no surprise that healthcare stocks were beaten last year. Overall, the sector was down 11%, well below the S&P 500 which climbed more than 15%.
However, the market is always looking to the future with a particular eye on innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late trials for drugs that can deliver groundbreaking results for conditions that continue to plague our world.
This is the object of this presentation. We have identified 7 healthcare actions that offer innovative ideas that will help improve patient outcomes. And in some cases, it will completely revolutionize medicine. These are also the stocks that analysts are looking for.
See the “7 healthcare stocks for innovation in 2021”.